Undetectable prostate‐specific antigen after short‐course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis‐free survival and prostate cancer‐specific survival

Background Optimal utilization of novel therapies for advanced prostate cancer is challenging without a validated surrogate efficacy endpoint. Ongoing trials are using durable undetectable prostate‐specific antigen (PSA) levels as a marker of efficacy. The clinical relevance of prolonged undetectable PSA after a short course of androgen deprivation therapy (ADT) is uncertain. Methods The University of Washington Caisis database was queried for...